PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Greystone Associates

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Syringe and Injector Device Innovation Lagging Drug Development in Some Key Areas Finds Greystone Research Associates - Greystone Research Associates examines the needs of injectable drug developers against the capabilities of evolving device designs - GreystoneAssociates.org
Syringe and Injector Device Innovation Lagging Drug Development in Some Key Areas Finds Greystone Research Associates

 

NewswireToday - /newswire/ - Amherst, NH, United States, 2013/12/17 - Greystone Research Associates examines the needs of injectable drug developers against the capabilities of evolving device designs - GreystoneAssociates.org.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Propelled by advances in materials science and design engineering software, progress in the healthcare sector is moving forward at an escalating rate. Drug delivery companies and their supply chain partners are being tested in this environment, as they strive to create devices and systems that can address the requirements of new drug therapies. The technology component of injection device design, development and fabrication has been arguably the most affected by this trend, and the strides that have been made in syringe and injector evolution have been impressive. But are injection devices at the forefront of this wave of innovation, or are they gating the launch of new injectables?

Not surprisingly, the answer is both. Advances in coatings and device designs have led to prefilled biologicals in patient-friendly drug-device combination products that were not possible just a few years ago. Prefilled drug cartridges have reduced the cost of injectable pens and autoinjectors, making them accessible to a larger segment of the chronically ill. Injectors with advanced features such as variable dosing, dose counters and audible cues are making self-administration safer for patients prescribed immune modulators with black box warnings. Similarly, dual chamber syringes and cartridges allow end-users to reconstitute injectable drugs without handling, measuring or manual dilution.

The other side of the title question is that, in spite of rapid progress in syringe and injector design and development, drug formulation is moving faster. Developers of advanced formulas that incorporate nanoparticles often have difficulty finding a device solution that keeps them on schedule. High-viscosity formulations that can be supplied and delivered in prefillable devices continue to challenge the industry. And certain protein and peptide drugs can create stability problems due to interaction with prefilled device materials, sometimes requiring long development delays or, if discovered post-launch, leading to product recalls and shortages.

To streamline the drug-device development process, drug developers are increasingly aligning themselves with device suppliers, increasing the level of concurrent engineering, identifying design challenges earlier and minimizing possible delays that could result. This trend represents risks for injectable drug firms competing for device solutions for their sophisticated formulations. It is also an opportunity for smaller device suppliers who are able to demonstrate the financial and technological resources to address the needs of injectable drug developers.

A new and comprehensive report on global injection device products and markets conducted by Greystone Research Associates is now available. The report Drug Injection Devices to 2018 provides analysis and assessments of drug injection devices across all major device categories syringes, pen injectors, autoinjectors, needle-free injectors and safety syringes and examines injectable drugs and combination products and their therapeutic markets, while also assessing market factors and market participants.

About Greystone Research Associates

Greystone Research Associates (greystoneassociates.org) is a medical technology consulting firm focused on the areas of medical market strategy, product commercialization, venture development, and market research. We assist medical and healthcare market participants in achieving their business objectives through the creation of detailed development strategies, product commercialization programs, and comprehensive market and technology research and analysis. Our market research publications are designed, researched and written to provide timely and insightful information and data on focused market segments, with the aim of providing market participants with the essential knowledge to refine and execute their marketing plans and financial targets.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Greystone Associates

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Syringe and Injector Device Innovation Lagging Drug Development in Some Key Areas Finds Greystone Research Associates

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Mark Smith - GreystoneAssociates.org 
603-595-4340 mksmith[.]greystoneassociates.org
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Greystone Associates securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Greystone Associates / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

First Pulmonary Embolism Patients in Hong Kong Treated with the EKOS® System
Ipsen to Acquire Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Genentech’s Cancer Immunotherapy Tecentriq® (Atezolizumab) Priority Review in Additional Type of Advanced Bladder Cancer
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) for Myopic Choroidal Neovascularization
Sugar Element of Keratan Sulfate Halts the Progress of Emphysema Finds RIKEN
Exelixis and Ipsen Amend Exclusive Licensing Agreement for the Commercialization and Development of Cabozantinib to Include Canada
FDA Extends Review of Application for OCREVUS™ (Ocrelizumab)
MDxHealth Announces AceCGT Life Science Limited as the Exclusive Distributor for SelectMDx in Hong Kong and Macao China
Pulse Certified As A Level Four Multichannel Content Agency by Veeva Systems
BD Launches Advanced Prefillable Syringe for Higher Volume Injection of Biologics
Sartorius Announces Expansion of Sartorius Stedim Cellca
Frost & Sullivan Commends Nemaura for Developing Superior Transdermal Drug Delivery Technology Platforms, the Memspatch and Micropatch
Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
BD Integrating Technology, Expertise and Services to Provide Comprehensive Medication Management
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  Intrinsic Executive Search Ltd

Visit  JobsWare.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)